Please join us on September 23rd, 2014 at 1:00 p.m. for a webinar where we'll discuss the recent statements from the Department of Justice and the U.S. Securities and Exchange Commission describing the susceptibility of pharmaceutical and medical device companies in regards to FCPA enforcement. Key questions that will be addressed include:
- Why does the FCPA seem to attract government investigations into the practices of health care companies specifically, and what should my company be worried about?
- What FCPA enforcement actions have the DOJ and SEC brought against health care companies in recent years, and what are the lessons learned from these actions?
- Does the increased level of focus on China indicate a new trend of global anti-bribery enforcement?
- What simple best practices can health care companies implement to reduce the chances of governmental FCPA scrutiny?
The discussion will be led by our colleagues in the FCPA Practice, Paul Pelletier and Aaron Tidman.
We hope you can join us. Please click here to register.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
